Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer; The MANTA Phase 2 Randomized Clinical Trial
Peter Schmid, FRCP, PhD; Matthias Zaiss, MD; Catherine Harper-Wynne, MD; Marta Ferreira, MD;
Sidharth Dubey, FRCR; Stephen Chan, FRCP, DM; Andreas Makris, FRCP; Gia Nemsadze, MD, PhD;
Adrian M. Brunt, FRCP; Sherko Kuemmel, MD, PhD; Isabel Ruiz, MD; Antonia Perelló, MD; Anne Kendall, MD;
Janet Brown, MD; Hartmut Kristeleit, FRCP; John Conibear, MD; Cristina Saura, MD; Julien Grenier, MD;
Károly Máhr, MD; Michael Schenker,MD, PhD; Joohyuk Sohn, MD, PhD; Keun Seok Lee, MD, PhD;
Christopher J. Shepherd, PhD; Elisabeth Oelmann, MD, PhD; Shah-Jalal Sarker, PhD; Aaron Prendergast, MSc;
Patricia Marosics, BSc; Atiyyah Moosa, BSc; Cheryl Lawrence, BPharm; Carike Coetzee, MSc; Kelly Mousa, MSc;
Javier Cortés, MD, PhD
Manuscrito
JAMA network
2019
MANTA
